“Glucagon-Like Peptide-1 Receptor Agonist Treatment in Type 1 Diabetes: A Review of Current Evidence and Rationale for Use”. 2023. Canadian Diabetes & Endocrinology Today 1 (3): 21–26. https://doi.org/10.58931/cdet.2023.1318.